Glycated Hemoglobin is Independently Associated with Albuminuria in Young Nondiabetic People with Obesity: A Cross-Sectional Study

Yanli Li
Juan Shi
Xiaolin Huang
Rui Wang
Bin Gu
Peiwen Liang
Shaoqian Zhao
Yingkai Sun
Wen Liu
Yuying Deng
Liuqing Xi
Dandan Zhao
Dalong Song
Yanan Cao
Yifei Zhang
Weiqiong Gu
Jie Hong

Background: The aim of this study was to explore the association between glycated hemoglobin (HbA1c) level and albuminuria in young nondiabetic people with obesity.

Material/Methods: A total of 537 young nondiabetic people with obesity were enrolled in this cross-sectional study, which was approved by the Rui-jin Hospital Ethics Committee. Albuminuria was defined as a urinary albumin-to-creatinine ratio (ACR) ≥30 mg/g. Multivariate logistic regression was used to analyze the association between HbA1c level and albuminuria.

Results: Urinary ACR progressively increased across the tertiles of HbA1c level (P for trend <0.05). HbA1c levels were positively associated with the risk of albuminuria in the logistic regression analysis after adjustment for confounding factors. The adjusted odds ratio (OR) for albuminuria was 3.72 (95% confidence interval [CI], 1.25–11.00; P=0.017) when comparing between the highest (≥5.7%) and lowest tertiles of HbA1c level (<5.3%). Moreover, an increment of 1 SD in HbA1c level increased the risk of albuminuria in a fully adjusted model (OR, 1.73; 95% CI, 1.25–2.46).

Conclusions: These data suggest that HbA1c level was independently associated with albuminuria in young nondiabetic people with obesity.

MeSH Keywords: Albuminuria • Hemoglobin A, Glycosylated • Obesity

Full-text PDF: http://www.medscimonit.com/abstract/index/idArt/902450
Background

Chronic kidney disease (CKD), which is characterized by reduced estimated glomerular filtration rate (eGFR) and/or albuminuria, is an increasing global concern. Albuminuria, defined as a urinary albumin-to-creatinine ratio (ACR) ≥30 mg/g, is an early marker of CKD and an independent predictor of cardiovascular disease (CVD) [1,2]. Albuminuria has been reported to increase the risk of cardiovascular events, cardiovascular mortality, and all-cause mortality in diabetic and nondiabetic individuals [3–5]. Numerous studies have focused on albuminuria in diabetic patients and the general population [6–9]. However, in people with obesity, the risk factors of albuminuria have not yet been fully elucidated. Only a few studies have revealed that albuminuria is associated with several obesity indicators, including waist circumference, body mass index (BMI), and body fat in obese patients with or without diabetes. In addition, some metabolic parameters, such as random plasma glucose, blood pressure, and triglyceride levels, were also associated with albuminuria in overweight or obese patients with or without diabetes [10,11].

Glycated hemoglobin (HbA1c) level, which is a useful indicator of glycemic control for the previous 3 months, is an independent risk factor of CVD in patients with or without diabetes [12–14]. Recently, HbA1c level has been shown to increase the risks of cardiovascular adverse outcomes and all-cause mortality in overweight and obese patients with diabetes [15]. Accumulating evidence has revealed that HbA1c level is positively associated with albuminuria and is regarded as a risk factor of albuminuria in normal-weight diabetic patients. However, few studies have examined the relationship between HbA1c level and albuminuria in young nondiabetic people with obesity.

Therefore, the purpose of our cross-sectional study was to evaluate the association between HbA1c level and albuminuria in young nondiabetic people with obesity, after controlling for some potential confounders.

Material and Methods

Study subjects

In accordance with the recommendations of the Working Group on Obesity in China, young nondiabetic people with obesity were enrolled consecutively at the Shanghai Clinical Center for Endocrine and Metabolic Diseases. Young people with obesity were defined as those having a BMI ≥28 kg/m² and an age <30 years. According to the Diagnosis and Classification of Diabetes Mellitus in the guidelines established by the American Diabetes Association in 2010 [16], a fasting plasma glucose (FPG) level ≥7.0 mmol/L and a 2-h plasma glucose (2-h PG) level ≥11.1 mmol/L during a 75-g oral glucose tolerance test, or a HbA1c level ≥6.5%, was defined as diabetes. The exclusion criteria were: 1) presence of acute or chronic heart disease, mental disorder, infection, or malignancy; 2) use of any antihypertensive or antidiabetic medication before enrollment; 3) missing HbA1c, urinary albumin, or urinary creatinine data; 4) eGFR <15 mL/min/1.73 m². Finally, 537 young nondiabetic people with obesity were included for further analysis. Informed consent was obtained from each participant. All the protocols were approved by the Rui-jin Hospital Ethics Committee, Shanghai Jiao-Tong University School of Medicine.

Clinical and biochemical measurements

Anthropometric indices, including height, body weight, waist circumference (WC), hip circumference, and neck circumference, were measured. BMI was calculated as weight (kg) divided by height squared (m²). Using a mercury sphygmomanometer, blood pressure was measured on the right arm with the patients in the seated position after at least a 15-min rest. The patients fasted from 8:00 p.m. the day before the glucose tolerance test. At 8:00 a.m. on the test day, a 75-g oral glucose tolerance test was performed, and venous blood samples were collected for measurement of FPG and 2-h PG levels using the glucose oxidase method on an autoanalyzer (Modular P800; Roche, Basel, Switzerland). Triglyceride (TG), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-c), low-density lipoprotein cholesterol (LDL-c), alanine aminotransferase (ALT), aspartate aminotransferase (AST), serum creatinine, and gamma-glutamyl transpeptidase (GGT) levels were measured using an autoanalyzer (Modular E170; Roche, Basel, Switzerland). HbA1c level was measured using high-performance liquid chromatography (BIO-RADD-10, USA). A first-voided, early-morning urine sample was collected to measure urinary albumin and creatinine concentrations. Urinary albumin concentration was determined using an immunoturbidimetric method (Beijing Atom High-Tech, Beijing, China), and urinary creatinine concentration was measured using Jaffe’s kinetic method on an autoanalyzer (Hitachi 7600-020, Tokyo, Japan). These laboratory parameters were assessed in the Clinical Laboratory for Endocrinology, Shanghai Institution of Endocrine and Metabolic Diseases, which was certified by the College of American Pathologists.

Definition and calculation

Urinary ACR (mg/g) was calculated by dividing the urinary albumin concentration by the urinary creatinine concentration. Albuminuria was defined as a urinary ACR ≥30 mg/g (microalbuminuria: 30–299 mg/g, macroalbuminuria: ≥300 mg/g). eGFR was calculated using the abbreviated modification of diet in renal disease formula as follows: eGFR=186×[serum creatinine³/88.4]×[ideal body weight/1.73m²]³. Using a mercury sphygmomanometer, blood pressure was measured on the right arm with the patients in the seated position after at least a 15-min rest. The patients fasted from 8:00 p.m. the day before the glucose tolerance test. At 8:00 a.m. on the test day, a 75-g oral glucose tolerance test was performed, and venous blood samples were collected for measurement of FPG and 2-h PG levels using the glucose oxidase method on an autoanalyzer (Modular P800; Roche, Basel, Switzerland). Triglyceride (TG), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-c), low-density lipoprotein cholesterol (LDL-c), alanine aminotransferase (ALT), aspartate aminotransferase (AST), serum creatinine, and gamma-glutamyl transpeptidase (GGT) levels were measured using an autoanalyzer (Modular E170; Roche, Basel, Switzerland). HbA1c level was measured using high-performance liquid chromatography (BIO-RADD-10, USA). A first-voided, early-morning urine sample was collected to measure urinary albumin and creatinine concentrations. Urinary albumin concentration was determined using an immunoturbidimetric method (Beijing Atom High-Tech, Beijing, China), and urinary creatinine concentration was measured using Jaffe’s kinetic method on an autoanalyzer (Hitachi 7600-020, Tokyo, Japan). These laboratory parameters were assessed in the Clinical Laboratory for Endocrinology, Shanghai Institution of Endocrine and Metabolic Diseases, which was certified by the College of American Pathologists.

Definition and calculation

Urinary ACR (mg/g) was calculated by dividing the urinary albumin concentration by the urinary creatinine concentration. Albuminuria was defined as a urinary ACR ≥30 mg/g (microalbuminuria: 30–299 mg/g, macroalbuminuria: ≥300 mg/g). eGFR was calculated using the abbreviated modification of diet in renal disease formula as follows: eGFR=186×[serum creatinine³/88.4]×[ideal body weight/1.73m²]³.
In the present cross-sectional study, we found that HbA1c level was independently associated with albuminuria in young
nondiabetic people with obesity. Our results suggest that HbA1c level is an important risk factor of albuminuria, independent of other anthropometric and metabolic variables such as BMI, blood pressure, FPG level, and TG level, in young non-diabetic people with obesity.

The association between HbA1c level and albuminuria has been previously explored in many studies in subjects with or without diabetes [6,19–22]. In patients with type 1 diabetes, the risk of microalbuminuria was strongly associated with HbA1c level [6]. The UK Prospective Diabetes Study revealed that HbA1c level was an independent risk factor of albuminuria in type 2 diabetes in >15 years of follow-up [22]. Guo et al. also reported that HbA1c level was independently associated with albuminuria in Chinese individuals with type 2 diabetes [23]. Moreover, HbA1c level was reported to be associated with low-grade albuminuria, which is an early marker of CVD in middle-aged and elderly Chinese adults, irrespective of diabetes status [24]. However, these studies mainly focused on diabetic patients and the general population. Few studies have examined the relationship between HbA1c level and albuminuria in nondiabetic people with obesity. In addition, several studies identified some risk factors of albuminuria in people with obesity. Pehlivan et al. showed that blood pressure, random plasma glucose, and other risk factors were determinants of microalbuminuria in people with obesity in primary care units [25]. Lurbe et al. reported that in young people with obesity, albuminuria mainly depends on metabolic factors, including WC and TG level [11]. Intrahepatic triglyceride content was reported to be independently associated with albuminuria in adults with obesity [26]. These studies investigated some determinants of albuminuria in people with obesity, regardless of diabetes.

### Table 1. Characteristics of study subjects by HbA1c level.

|                     | Tertile 1 (≤5.3%) (n=149) | Tertile 2 (5.4–5.6%) (n=177) | Tertile 3 (≥5.7%) (n=211) | P for trend |
|---------------------|---------------------------|-------------------------------|---------------------------|-------------|
| Age (years)         | 21.5±5.7                  | 21.9±6.9                      | 23.7±7.5                  | 0.0019      |
| Males (%)           | 65 (43.62)                | 78 (44.07)                    | 79 (37.44)                | 0.2093      |
| BMI (kg/m²)         | 34.8±5.0                  | 35.7±5.7                      | 37.5±5.7                  | <0.0001     |
| WC (cm)             | 107.3±11.0                | 111.2±12.3                    | 113.0±15.0                | <0.0001     |
| TG (mmol/L)         | 1.43 (1.02–1.95)          | 1.41 (1.02–1.87)              | 1.65 (1.24–2.20)          | 0.0012      |
| TC (mmol/L)         | 4.35±0.89                 | 4.42±0.86                     | 4.81±1.38                 | 0.034       |
| LDL-c (mmol/L)      | 2.69±0.76                 | 2.83±0.65                     | 2.91±0.77                 | 0.007       |
| HDL-c (mmol/L)      | 1.07±0.25                 | 1.06±0.22                     | 1.07±0.26                 | 0.959       |
| SBP (mmHg)          | 126.6±16.1                | 127.6±15.1                    | 128.6±17.1                | 0.2753      |
| DBP (mmHg)          | 81±9.8                    | 81.8±10.9                     | 82.7±11.9                 | 0.176       |
| FPG (mmol/L)        | 4.9 (4.63–5.20)           | 5.0 (4.70–5.34)               | 5.3 (4.89–5.62)           | <0.0001     |
| 2-hPG (mmol/L)      | 6.4 (5.5–7.6)             | 6.7 (5.8–7.8)                 | 7.7 (6.5–9.2)             | <0.0001     |
| HbA1C (%)           | 5.10±0.21                 | 5.50±0.09                     | 6.04±0.44                 | <0.0001     |
| Urinary ACR         | 6.13 (4.55–11.19)         | 6.77 (4.76–11.18)             | 8.70 (5.72–16.18)         | 0.0064      |
| eGFR (ml/min per 1.73 m²) | 139.9 (122.9–160.8)     | 145.3 (125.9–168.7)           | 148.2 (127.7–175.3)       | 0.505       |
| HOMA-IR             | 4.11 (2.78–5.93)          | 4.63 (3.32–6.03)              | 5.76 (4.19–8.34)          | <0.0001     |
| HOMA-β              | 2.80 (1.97–3.84)          | 2.84 (1.98–3.88)              | 2.85 (2.00–4.50)          | 0.141       |

Data are means ±SD or geometric means (interquartile range) for continuous variables, or percentages for categorical variables. P for trend was calculated by linear regression analysis across groups. BMI – body mass index; WC – waist circumference; TG – triglyceride; TC – total cholesterol; LDL-c – low-density lipoprotein cholesterol; HDL-c – high-density lipoprotein cholesterol; SBP – systolic blood pressure; DBP – diastolic blood pressure; FPG – fasting plasma glucose; 2-h PG – 2-h postload glucose; eGFR – estimated glomerular filtration rate; Urinary ACR – albumin-to-creatinine ratio; HbA1c – glycated hemoglobin; HOMA-IR – homeostasis model assessment of insulin resistance; HOMA-β – homeostasis model assessment of β cell function.
However, the association between HbA1c level and albuminuria in nondiabetic people with obesity, irrespective of some metabolic factors, is not fully understood. Therefore, in this cross-sectional study, we investigated young nondiabetic people with obesity to identify an independent relationship between HbA1c level and albuminuria. These results indicated that HbA1c was positively associated with albuminuria in young nondiabetic people with obesity. However, our cross-sectional study does not establish a cause-effect relationship between HbA1c level and albuminuria in young nondiabetic people with obesity. Whether HbA1c plays a causative role in incident albuminuria young nondiabetic people with obesity remains unknown. Further longitudinal studies aimed at validating the association of HbA1c level with incident albuminuria or incident CKD among young nondiabetic people with obesity are warranted.

However, the pathophysiological mechanisms linking HbA1c level and albuminuria remain unknown. Previous studies speculated that the association between HbA1c level and albuminuria in nondiabetic individuals may be the same as that in diabetic patients [19]. Higher HbA1c levels, which indicate chronic hyperglycemia over the prior 3 months, may contribute...
to glomerular hyperperfusion and hyperfiltration, consequently causing progressive glomerular damage until macroalbuminuria appears [27]. In addition, chronic hyperglycemia may induce greater oxidative stress and endothelial dysfunction in the kidney, which leads to increased leakage of albumin [28].

The present study has several limitations. First, the lack of cross-sectional and observational studies limited our ability to detect causality between HbA1c level and albuminuria. Whether HbA1c concentration and albuminuria are causally associated cannot be concluded from this cross-sectional study alone. Second, the subjects in the study were enrolled at only 1 clinic. Therefore, the ability to generalize our findings may be limited. Caution is also required in interpreting our results due to possible participants bias. Third, due to the missing information for variables such as the duration of obesity, smoking status, alcohol intake, physical activity, and inflammatory factors, these potential risk factors were not included in the analysis. Last, a single morning spot urine sample for measurement of ACR may not reflect the true level of urinary albumin excretion.

In conclusion, our study showed that HbA1c level was independently associated with albuminuria in young nondiabetic people with obesity. This study may support measurement of HbA1c level in young obese patients to detect albuminuria or CKD, even in the absence of diabetes.

Conclusions
HbA1c level was independently associated with albuminuria and might be an indicator of albuminuria in young obese patients without diabetes.

Declaration of interest
The authors declare no conflicts of interest.

Acknowledgments
This manuscript has been edited by the FSeditor English language editing service.

References:

1. Chen F, Yang W, Weng J et al: Albuminuria: Prevalence, associated risk factors and relationship with cardiovascular disease. J Diabetes Investig, 2014; 5: 464–71
2. Cao JJ, Barzilay JI, Peterson D et al: The association of microalbuminuria with clinical cardiovascular disease and subclinical atherosclerosis in the elderly: The Cardiovascular Health Study. Atherosclerosis, 2006; 187: 572–77
3. Gerstein HC, Mann JF, Yi Q et al: Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and non diabetic individuals. JAMA, 2001; 286: 421–26
4. Romundstad S, Holmen J, Kvenild K et al: Microalbuminuria and all-cause mortality in 2,089 apparently healthy individuals: A 4.4-year follow-up study. The Nord-Trondelag Health Study (HUNT), Norway. Am J Kidney Dis, 2003; 42: 466–73
5. Hillege HL, Fidler V, Diercks GF et al: Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 2002; 106: 1777–82
6. Krolewski AS, Laffel LM, Krolewski M et al: Glycosylated hemoglobin and the risk of microalbuminuria in patients with insulin-dependent diabetes mellitus. New Engl J Med, 1995; 332: 1251–55
7. Ren M, Sun K, Li F et al: Association between obesity measures and albuminuria: A population-based study. J Diabetes Complications, 2016; 30: 451–56
8. Sun K, Li F, Lin D et al: Serum gamma-glutamyltransferase is associated with albuminuria: A population-based study. PLoS One, 2014; 9: e114970
9. Penno G, Solini A, Zoppini G et al: Independent correlates of urinary albumin excretion within the normalalbuminuric range in patients with type 2 diabetes: The Renal Insufficiency And Cardiovascular Events (RIACE) Italian Multicentre Study. Acta Diabetologica, 2015; 52: 971–81
10. Hoffmann IS, Jimenez E, Cubeddu LX: Urinary albumin excretion in lean, overweight and obese glucose tolerant individuals: Its relationship with dyslipidaemia, hyperinsulinemia and blood pressure. J Hum Hypertens, 2001; 15: 407–12
11. Lurbe E, Torro MJ, Alvarez J et al: Prevalence and factors related to urinary albumin excretion in obese youths. J Hypertens, 2013; 31: 2230–36; discussion 2236
12. Ikeda F, Doi Y, Ninomiya T et al: Haemoglobin A1c even within non-diabetic level is a predictor of cardiovascular disease in a general Japanese population: the Hisayama Study. Cardiovasc Diabetol, 2013; 12: 164
13. Stratton IM, Adler AI, Neil HA et al: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ, 2000; 321: 405–12
14. Selvin E, Steffes MW, Zhu H et al: Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. New Engl J Med, 2010; 362: 800–11
15. Anderson C, van Gaal L, Caterson ID et al: Relationship between HbA1c levels and risk of cardiovascular adverse outcomes and all-cause mortality in overweight and obese cardiovascular high-risk women and men with type 2 diabetes. Diabetologia, 2012; 55: 2348–55
16. American Diabetes Association: Diagnosis and classification of diabetes mellitus. Diabetes Care, 2010; 33(Suppl. 1): S62–69
17. De Leeuw PW, Thijs L, Birkenhager WH et al: Prognostic significance of renal function in elderly patients with isolated systolic hypertension: Results from the Syst-Eur trial. J Am Soc Nephrol, 2002; 13: 2213–22
18. Matthews DR, Hosker JP, Rudenski AS et al: Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia, 1985; 28: 412–19
19. Kang SH, Jung da J, Choi EW et al: HbA1c levels are associated with chronic kidney disease in a non-diabetic adult population: A Nationwide Survey (KNHANES 2011–2013). PLoS One, 2015; 10: e0145827
20. Gerstein HC, Pogue I, Mann JF et al: The relationship between dysglycaemia and cardiovascular and renal risk in diabetic and non-diabetic participants in the HOPE study: A prospective epidemiological analysis. Diabetologia, 2005; 48: 1749–55
21. Hernandez D, Espejo-Gil A, Bernal-Lopez MR et al: Association of HbA1c and cardiovascular and renal disease in an adult Mediterranean population. BMC Nephrol, 2013; 14: 151
22. Rethnakaran R, Cull CA, Thorne KI et al: Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74. Diabetes, 2006; 55: 1832–39
23. Guo K, Zhang L, Zhao F et al: Prevalence of chronic kidney disease and associated factors in Chinese individuals with type 2 diabetes: Cross-sectional study. J Diabetes Complications, 2016; 30: 803–10
24. Huang X, Zhou Y, Xu B et al: Glycated haemoglobin A1c is associated with low-grade albuminuria in Chinese adults. BMJ Open, 2015; 5: e007429

25. Pehlivam E, Ozen G, Taskapan H et al: Identifying the determinants of microalbuminuria in obese patients in primary care units: the effects of blood pressure, random plasma glucose and other risk factors. J Endocrinol Invest, 2016; 39: 73–82

26. Pan LL, Zhang HI, Huang ZF et al: Intrahepatic triglyceride content is independently associated with chronic kidney disease in obese adults. A cross-sectional study. Metabolism, 2015; 64: 1077–85

27. Nelson RG, Bennett PH, Beck GJ et al: Development and progression of renal disease in Pima Indians with non-insulin-dependent diabetes mellitus. Diabetic Renal Disease Study Group. New Engl J Med, 1996; 335: 1636–42

28. Skrha J, Soupal J, Skrha J Jr., Prazny M: Glucose variability, HbA1c and microvascular complications. Rev Endocr Metab Disord, 2016; 17(1): 103–10